"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".

{"article_title":"\"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil\".","author":"Jardim DL et al.","journal_title":"Clinical genitourinary cancer","issn":"1938-0682","isbn":"","publication_date":"2023 Apr","volume":"21","issue":"2","first_page":"e58","page_count":"","accession_number":"36266221","doi":"10.1016\/j.clgc.2022.09.005","publisher":"Elsevier","doctype":"Journal Article","subjects":"Brazil; Prostatic Neoplasms, Castration-Resistant diagnosis; Prostatic Neoplasms, Castration-Resistant therapy; Humans; Male; Neoplasm Staging; Antineoplastic Agents therapeutic use; Androgen Receptor Antagonists therapeutic use; Consensus; Brazil; Osteoclasts","interest_area":["Oncology"," Obstetrics & Gynecology"],"abstract":"Introduction: Non-metastatic, castration-resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen-receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC. Given recent developments in this field, we update our recommendations for the management of nmCRPC. Methods: A panel of 51 invited medical oncologists and urologists convened in May of 2021 with the aim of discussing and providing recommendations regarding the most relevant issues concerning staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up in nmCRPC. Panel members considered the available evidence and their practical experience to address the 73 multiple-choice questions presented. Results: Key recommendations and findings include the reliance on prostate-specific antigen doubling time for treatment decisions, the absence of a clear preference between conventional and novel (i.e., positron-emission tomography-based) imaging techniques, the increasing role of ARSis in various settings, the general view that ARSis have similar efficacy. Panelists highlighted the slight preference for darolutamide, when safety is of greater concern, and a continued need to develop high-level evidence to guide the intensity of follow-up in this subset of prostate cancer. Discussion: Despite the limitations associated with a consensus panel, the topics addressed are relevant in current practice, and the recommendations can help practicing clinicians to provide state-of-the-art treatment to patients with nmCRPC in Brazil and other countries with similar healthcare settings. Copyright \u00a9 2022. Published by Elsevier Inc.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=36266221&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Jardim DL, Gon\u00e7alves E Silva A, Pompeo ASFL, Sarkis AS, Cardoso APG, Sasse AD, Fay AP, Soares A, Pompeo ACL, Carneiro A, Kann AG, Fogassa C, De Freitas CH Junior, Chade DC, Herchenhorn D, De Almeida DVP, Da Rosa DAR, Wiermann EG, Schutz FAB, Kater FR, De Moura F, Korkes F, Meyer F, De Oliveira FNG, Sabino F, Almeida GL, Avan\u00e7o G, Guimaraes GC, Lemos GC, Carvalhal GF, Kim H, Morbeck IP, Campagnari JC, Rinck JA Junior, Da Ponte JRT, Da Trindade KM, Atem L, Borges L, Nogueira LM, Batista LTEA, Maia MC, Sadi MV, Rocha MAA, Luz MA, Smaletz O, Lages PSM, Matuda RMK, Reis RBD, Indio RF, Fernandes RC, Cavallero SR, Souza VC, Busato W Jr, Alfer W Junior, Maluf F","Journal_Info":"Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE","Publication_Type":"Journal Article; Research Support, Non-U.S. Gov't","Published_Date":"2023-04-01","Source":"Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Apr; Vol. 21 (2), pp. e58-e69. Date of Electronic Publication: 2022 Sep 10.","Languages":"English","Electronic_ISSN":"1938-0682","MeSH_Terms":"Prostatic Neoplasms, Castration-Resistant*\/diagnosis , Prostatic Neoplasms, Castration-Resistant*\/therapy, Humans ; Male ; Neoplasm Staging ; Antineoplastic Agents\/therapeutic use ; Androgen Receptor Antagonists\/therapeutic use ; Consensus ; Brazil ; Osteoclasts","Subjects":"Humans, Male, Neoplasm Staging, Antineoplastic Agents therapeutic use, Androgen Receptor Antagonists therapeutic use, Consensus, Brazil, Osteoclasts, Prostatic Neoplasms, Castration-Resistant diagnosis, Prostatic Neoplasms, Castration-Resistant therapy","Title_Abbreviations":"Clinical genitourinary cancer","Volume":"21"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"36266221","RelevancyScore":"913","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"913.340393066406"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=36266221&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=36266221&authtype=shib&custid=ns346513&group=main&profile=eds"}